PD-L1 inhibitor monoclonal antibody injection, infused in outpatient oncology clinics and specialized cancer hospitals. Biotech firms and distributors provide to healthcare procurement teams for incorporation into immune checkpoint blockade therapies in advanced malignancy treatments.